Spyre Therapeutics, Inc. (SYRE)
NASDAQ: SYRE · Real-Time Price · USD
27.14
-0.37 (-1.33%)
Nov 21, 2024, 12:04 PM EST - Market open
Spyre Therapeutics Stock Forecast
Stock Price Forecast
The 7 analysts with 12-month price forecasts for Spyre Therapeutics stock have an average target of 48.57, with a low estimate of 31 and a high estimate of 65. The average target predicts an increase of 78.99% from the current stock price of 27.14.
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for SYRE stock from 9 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Jun '24 | Jul '24 | Aug '24 | Sep '24 | Oct '24 | Nov '24 |
|---|---|---|---|---|---|---|
| Strong Buy | 3 | 3 | 3 | 3 | 4 | 4 |
| Buy | 3 | 4 | 4 | 5 | 5 | 5 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 6 | 7 | 7 | 8 | 9 | 9 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Baird | Baird | Buy Maintains $50 → $65 | Buy | Maintains | $50 → $65 | +139.54% | Nov 13, 2024 |
| Guggenheim | Guggenheim | Strong Buy Maintains $50 → $65 | Strong Buy | Maintains | $50 → $65 | +139.54% | Oct 25, 2024 |
| Wedbush | Wedbush | Buy Initiates $45 | Buy | Initiates | $45 | +65.84% | Sep 4, 2024 |
| Evercore ISI Group | Evercore ISI Group | Buy Initiates n/a | Buy | Initiates | n/a | n/a | Jul 16, 2024 |
| Wells Fargo | Wells Fargo | Buy Maintains $35 → $40 | Buy | Maintains | $35 → $40 | +47.41% | May 13, 2024 |
Financial Forecast
Revenue This Year
3.57M
from 886.00K
Increased by 302.93%
Revenue Next Year
5.27M
from 3.57M
Increased by 47.62%
EPS This Year
-3.77
from -49.12
EPS Next Year
-3.97
from -3.77
Revenue Forecast
| Revenue | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | 21.0M | 31.5M | 1.1M | ||
| Avg | 3.6M | 5.3M | 255,000 | ||
| Low | n/a | n/a | n/a |
Revenue Growth
| Revenue Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | 2,270.2% | 782.4% | -80.1% | ||
| Avg | 302.9% | 47.6% | -95.2% | ||
| Low | - | - | - |
EPS Forecast
| EPS | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | -2.96 | -2.06 | -2.57 | ||
| Avg | -3.77 | -3.97 | -4.91 | ||
| Low | -4.21 | -6.59 | -7.18 |
EPS Growth
| EPS Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | - | - | - | ||
| Avg | - | - | - | ||
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.